Fail

Script Data, Part 4 – A Tale of Two Drugs, Continued. – MNKD, SNY

An update in our ongoing examination of the performance of two recent drug launches from Sanofi (SNY). One is Toujeo, an injectable. The other is Mannkind‘s (MNKD) much hyped, beloved by retail investors, inhaled insulin Afrezza. These two drugs are both for the treatment of diabetes. Sanofi uses the same salesforce, who would be detailing the exact same doctors for both drugs. Can you spot the commercial flop? Remember folks, we are looking for “up and to the right”, we don’t want to see the patient flatlining.

Spot the dismal, pathetic, failure.

Spot the dismal, pathetic, failure.

Can Jefferies’ resident Mannkind moron Shaunak Deepak? Just for fun we’ve extended out the Afrezza data for the full 23 weeks it has been on the market. Toujeo has only been on the market for four months as of the last sales update.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

UPDATED – Script Data, Part 3 – A Tale of Two Drugs – MNKD, SNY

UPDATED 23 June 2015 to include weeks 12 and 13 post launch for both drugs.

Spot the failure. Two recent drug launches, using the exact same salesforce from Sanofi (SNY), targeting the exact same doctors. Presenting Toujeo vs. Afrezza.

A Tale of Two Drug Launches

A Tale of Two Drug Launches

Can you spot the commercial flop? Can Jefferies’ resident Mannkind (MNKD) moron Shaunak Deepak?

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Script Data, Script Data, Updated – GALE, MNKD, KERX, etc.

Back by popular demand, the chart showing the worst drug launches in recent memory, original here, has been updated to include a few more weeks of data, and the relaunch of dreadful Galena’s (GALE) me-too fentanyl product, Abstral.

Presented for your amusement:

Updated Chart of the Worst Drug (re)Launches in Recent Memory

Updated Chart of the Worst Drug (re)Launches in Recent Memory

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Adam S. Gottbetter’s Very Bad Day – EKSO, NTRP, CURM, & More

UPDATE: Read Adam S. Gottbetter’s plea agreement:

USA v GOTTBETTER

Delusional, self-important, penny stock lawyer Adam S. Gottbetter is having a really bad day. He was first exposed in Barron’s in a great piece by Bill Alpert in 2009. Read it here. Today, 6 years later, in an amazingly rare action against a lawyer, the SEC charged Gottbetter with a litany of offenses.

(more…)

Script data, script data, on the wall, who’s the worst bio-dreck of them all? – KERX, GALE, MNKD

One of our favorite things to do at BuyersStrike! HQ is make fun of investors, usually retail, the sell side shills that prey on them, or very inexperienced buy-siders, who use ridiculous jargon like “PPS”, “uplist” and a new favorite “de-risked.”

Many investors seem to believe that with an approved drug a company magically becomes “de-risked”. In actuality, getting a drug approved (or buying an already approved drug) is only the beginning of the struggle for bio-dreck companies, moron management teams, and bagholder investors.

Presented for our, and hopefully your, amusement, is a graph of some of the very worst drug launches in recent memory.

(more…)

Vascular Biogenics and Schroedinger’s Trial Subjects – VBLT

Hard to believe it was only two weeks ago when the intrepid team at Neuralstem (CUR) issued a press release that showed they have mastered the ability to move back and forth along a linear timestream (catch up on that here). This week the crew at scandal plagued Vascular Biogenics (VBLT) has actually made that achievement look positively mundane.

VBLT has proven what quantum theory had long suggested, that quantum super-positioning exists. And perhaps VB-111 is the substance that can enable travel even Leary never thought possible.

Intrigued? Read on.

(more…)

What makes Neuralstem so incredible? (CUR)

If you have been following @buyersstrike on Twitter, you might see the occasional tweet about Neuralstem (CUR). Over here at BuyersStrike! HQ we find Neuralstem to be absolutely incredible. It takes a lot to stand above the crowd in the current world of bio-dreck mania. So, what makes this 2006 direct to the OTC-BB company so fascinating?

Well, the thing that makes this company so incredibly amazing (if they can successfully patent and commercialize) could make the company worth more than Apple, Tesla, Google, combined! Yes, more than all of them. Intrigued? Read on….

(more…)